Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
33.00
+0.11 (0.33%)
May 5, 2025, 4:00 PM EDT - Market closed
Royalty Pharma Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Royalty Pharma stock have an average target of 42.5, with a low estimate of 28 and a high estimate of 51. The average target predicts an increase of 28.79% from the current stock price of 33.00.
Analyst Consensus: Strong Buy
* Price targets were last updated on Oct 25, 2024.
Analyst Ratings
The average analyst rating for Royalty Pharma stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $60 → $40 | Strong Buy | Maintains | $60 → $40 | +21.21% | Oct 25, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $50 → $51 | Strong Buy | Maintains | $50 → $51 | +54.55% | Aug 14, 2024 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $48 → $51 | Buy | Maintains | $48 → $51 | +54.55% | Jul 11, 2024 |
| UBS | UBS | Strong Buy → Hold Downgrades $28 | Strong Buy → Hold | Downgrades | $28 | -15.15% | Jun 3, 2024 |
| B of A Securities | B of A Securities | Strong Buy Maintains $40 → $38 | Strong Buy | Maintains | $40 → $38 | +15.15% | Apr 12, 2024 |
Financial Forecast
Revenue This Year
2.97B
from 2.26B
Increased by 31.30%
Revenue Next Year
3.15B
from 2.97B
Increased by 5.82%
EPS This Year
4.58
from 1.91
Increased by 139.48%
EPS Next Year
5.19
from 4.58
Increased by 13.30%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.7B | 3.8B | 4.1B | ||
| Avg | 3.0B | 3.1B | 3.4B | ||
| Low | 2.4B | 2.6B | 2.6B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 63.1% | 26.9% | 31.4% | ||
| Avg | 31.3% | 5.8% | 7.4% | ||
| Low | 5.8% | -11.6% | -17.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 5.11 | 6.67 | 7.52 | ||
| Avg | 4.58 | 5.19 | 5.82 | ||
| Low | 3.94 | 4.15 | 4.61 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 167.1% | 45.6% | 44.9% | ||
| Avg | 139.5% | 13.3% | 12.1% | ||
| Low | 106.1% | -9.5% | -11.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.